摘要
目的 研究三代头孢联合喹诺酮药物治疗肺部感染多重耐药杆菌的效果和安全性。方法 选取咸宁市中医医院2019年6月至2020年7月收治的肺部感染多重耐药杆菌患者108例,按照随机数表法分为两组,每组各54例,B组予三代头孢(头孢曲松)治疗,A组予三代头孢(头孢哌酮钠舒巴坦钠)合并喹诺酮(左氧氟沙星)治疗,比较两组患者细菌清除率、治疗有效率、不良反应发生率及全血白细胞计数(WBC)、C反应蛋白(CRP)、降钙素原(PCT)水平。结果 A组细菌清除率为92.59%,高于B组的77.78%,差异有统计学意义(P <0.05);A组治疗总有效率为94.44%,高于B组的81.48%,差异有统计学意义(P <0.05);两组患者不良反应总发生率比较,差异无统计学意义(P> 0.05);治疗前两组患者WBC、CRP、PCT水平比较,差异无统计学意义(P> 0.05),治疗后A组患者各指标水平均低于B组,差异有统计学意义(P <0.05)。结论头孢哌酮钠舒巴坦钠(三代头孢)合并左氧氟沙星(喹诺酮)治疗肺部感染多重耐药杆菌患者的效果明显,有效提高患者体内病菌的清除率,并且具有较高的安全性。
Objective To investigate the efficacy and safety of third-generation cephalosporin combined with quinolone in the treatment of multidrug-resistant bacteria in pulmonary infection. Methods A total of 108 patients with pulmonary infection of multidrug-resistant bacteria admitted to and treated in the Xianning Hospital of Traditional Chinese Medicine from June 2019 to July 2020 were selected. And they were divided into group A(n=54) and group B(n=54) according to the random number table method. Group B was treated with third-generation cephalosporin(ceftriaxone), while group A was treated with third-generation cephalosporin(cefoperazone sodium and sulbactam sodium) combined with quinolone(levofloxacin). The bacterial clearance rate, the treatment response rate and the incidence of adverse reactions(ADRs), and the levels of whole blood leukocyte count(WBC), C-reactive protein(CRP) and procalcitonin(PCT) were compared between patients in the two groups. Results The bacterial clearance rate in group A was 92.59%, higher than 77.78% in group B,with statistically significant difference(P < 0.05). The total response rate in group A was 94.44%, higher than 81.48% in group B, with statistically significant difference(P < 0.05). There were no significant difference in the total incidence of ADRs between the two groups(P > 0.05). Before treatment, there were no statistically significant differences in the levels of WBC, CRP and PCT between the two groups(P > 0.05). After treatment,the levels of all indices in patients of group A were all lower than those of group B, with statistically significant differences(P < 0.05). Conclusion The combination of cefoperazone sodium and sulbactam sodium(thirdgeneration cephalosporin) and levofloxacin(quinolone) has obvious efficacy in the treatment of patients with multidrug-resistant bacteria in pulmonary infection, which effectively improves the bacteria clearance rate in patients and has relatively higher safety.
作者
王丹
WANG Dan(Quality Control Office,Xianning Hospital of Traditional Chinese Medicine,Hubei,Xianning 437100,China)
出处
《中国医药科学》
2022年第15期112-115,146,共5页
China Medicine And Pharmacy
关键词
三代头孢
喹诺酮
多重耐药
细菌清除率
安全性
Third-generation cephalosporin
Quinolone
Multidrug-resistant
Bacterial clearance rate
Safety
